- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01971346
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
Přehled studie
Detailní popis
Hypothesis: The balance between type I IFN and TNF determines the response to anti-TNF treatment. The goal of the proposed study is to address this hypothesis and demonstrate that the strength of the type I IFN signature in psoriatic skin is the major determinant of the clinical response to anti-TNF treatment.
Purpose: Determine the strength of the type I interferon and TNF signal in psoriatic skin prior to and during treatment with etanercept and correlate with degree of clinical improvement.
Study Population: up to 50 subjects, men or women over the age of 18 with clinically stable plaque psoriasis, who meet the wash out requirements and other exclusion criteria
Psoriatic patients will receive 100 mg etanercept per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months.
Procedures: Urine pregnancy test, TB test, photography, Physical Examinations, Skin Examinations, Study Drug, Peripheral blood and biopsies
Anticipated Results: We expect that patients with strong IFN-α signature in psoriatic skin along with weak TNF-α signature will have minimal response to anti-TNF treatment, while patients with the opposite pattern, weak IFN and strong TNF signature, will have significant clinical improvement.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 4
Kontakty a umístění
Studijní místa
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- University of Michigan Department of Dermatology
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- At least 18 years of age at screening.
- Clinically stable moderate to severe plaque psoriasis at screening and baseline.
Subject must be:
- A man or
- A woman who is surgically sterile or at least 3 years postmenopausal or
- A woman of childbearing potential who has had a negative pregnancy test within 7 days before the first dose of study drug.
- If the subject is sexually active, (s)he must agree to use a medically acceptable form of contraception during screening and throughout the study.
Exclusion Criteria:
- Grade 3 or 4 adverse events or infections within 28 days before screening, or between the screening visit and drug initiation.
- Active or chronic infection within 4 weeks before screening visit, or between the screening and baseline visits.
- Evidence of skin conditions other than psoriasis that would interfere with the evaluations of the effect of study medication on psoriasis.
- Use of oral psoralen with ultraviolet A (PUVA), oral retinoids, cyclosporine, alefacept, or any other systemic anti-psoriasis therapy within 28 days study drug initiation.
- Use of ulltraviolet B (UVB) therapy, topical steroids at no higher than moderate strength, topical vitamin A or D analog preparations, or anthralin with 14 days of study initiation.
- Prior or concurrent use of cyclophosphamide therapy
- Concurrent sulfasalazine therapy.
- Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to have antibodies to etanercept.
- Current enrollment in any other investigational device or investigational drug trial(s), or receipt of any other investigational agent(s) within 28 days before baseline visit.
- Use of any biologic drugs within 28 days of study drug initiation.
- Concurrent use of Anakinra.
- Severe comorbidities (diabetes mellitus requiring insulin; congestive heart failure (CHF) of any severity or myocardial infarction or cerebrovascular accident or transient ischemic attack within 3 months of screening visit; unstable angina pectoris, uncontrolled hypertension (sitting systolic blood pressure (BP) <80 mm Hg or > 160 or diastolic BP > 100 mm Hg), oxygen-dependent severe pulmonary disease, history of cancer within 5 years (other than resected cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer)
- Known history of tuberculosis (TB), or previous positive purified protein derivative (PPD) test. Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis medication.
- Known HIV-positive status or known history of any other immuno-suppressing disease.
- Concurrent or history of psychiatric disease that would interfere with ability to comply with study protocol or give informed consent.
- History of alcohol or drug abuse within 12 months of screening visit.
- Latex sensitivity [Nota Bene: only applicable if they are using prefilled syringe or prefilled SureClick™ autoinjector presentations]
- Exposure to hepatitis B or hepatitis C or to high risk factors for hepatitis B or C, such as intravenous drug use in patient.
- Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis, optic neuritis or seizure disorder.
- Use of a live vaccine 90 days prior to screening visit, or concurrent use of a live vaccine.
- Any condition or circumstances judged by the patient's physician[or the investigator or medically qualified study staff] to render this clinical trial detrimental or otherwise unsuitable for the patient's participation.
- History of non-compliance with other therapies.
- Pregnant or nursing females.
- Diagnosis of multiple sclerosis in first degree family relationship (parent, sibling or child)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Jiný: Etanercept
100 mg Etanercept injections per week for 3 months.
|
100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change in Psoriasis Area and Severity Index (PASI) Score
Časové okno: Baseline, 12 weeks
|
A cumulative change in PASI score from baseline to week 12 will be calculated for each patient.
The PASI is the industry standard to decrease/eliminate subjectivity in determining psoriasis severity.
It is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance.
The severity of plaque characteristics (erythema, thickness and scaling) for body regions (head, upper limbs, trunk and lower limbs) is combined with the degree of plaque involvement in each body region to determine a single PASI score in the range of 0 (no disease) and 72 (maximal disease).
|
Baseline, 12 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Tumor Necrosis Factor (TNF)-Alpha Signal Strength
Časové okno: Baseline, Week 6, Week 12
|
Strength of TNF-alpha signatures will be measured in skin of study subjects at initiation, during and after treatment.
The strength of these signals will be done using bioinformatic approach quantifying transcriptional signature of these cytokines.
The strength of the cytokine signals will be treated as a response variable in a univariate repeated measure analysis of variance, with PASI response profile and time as covariates.
PASI response profile will be categorized according to improvement in PASI score: responders (greater than 75% reduction in PASI from baseline), intermediate-responders (those with greater than 25% and less than 75% reduction in PASI from baseline), and non-responders (less than 25% reduction in PASI from baseline).
|
Baseline, Week 6, Week 12
|
Interferon (IFN)-Alpha Signal Strength
Časové okno: Baseline, Week 6, Week 12
|
Strength of IFN-alpha signatures will be measured in skin of study subjects at initiation, during and after treatment.
The strength of these signals in skin will be done using bioinformatic approach quantifying transcriptional signature of these cytokines.
The strength of the cytokine signals will be treated as a response variable in a univariate repeated measure analysis of variance, with PASI response profile and time as covariates.
PASI response profile will be categorized according to improvement in PASI score: responders (greater than 75% reduction in PASI from baseline), intermediate-responders (those with greater than 25% and less than 75% reduction in PASI from baseline), and non-responders (less than 25% reduction in PASI from baseline).
|
Baseline, Week 6, Week 12
|
Psoriasis Area and Severity Index (PASI) Response Profile
Časové okno: 12 Weeks
|
Subjects will be categorized according to improvement in Psoriasis Area and Severity Index (PASI) score: responders (greater than 75% reduction in PASI from baseline), intermediate-responders (those with greater than 25% and less than 75% reduction in PASI from baseline), and non-responders (less than 25% reduction in PASI from baseline).
|
12 Weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Johann Gudjonsson, MD PhD, University of Michigan
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Kožní choroby
- Kožní onemocnění, papuloskvamózní
- Psoriáza
- Fyziologické účinky léků
- Agenti periferního nervového systému
- Analgetika
- Agenti smyslového systému
- Protizánětlivé látky, nesteroidní
- Analgetika, nenarkotika
- Protizánětlivé látky
- Antirevmatika
- Imunosupresivní látky
- Imunologické faktory
- Gastrointestinální látky
- Etanercept
Další identifikační čísla studie
- Derm 652
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Psoriáza
-
ProgenaBiomeNáborPsoriáza | Psoriasis vulgaris | Psoriáza pokožky hlavy | Psoriatický plak | Psoriasis Universalis | Psoriáza na obličeji | Psoriáza hřebík | Psoriasis diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Genitální psoriáza | Psoriasis GeographicaSpojené státy
-
Herlev and Gentofte HospitalNáborInfarkt myokardu | Ischémie myokardu | Srdeční choroba | Kardiovaskulární choroby | Srdeční selhání | Mrtvice | Psoriáza | Srdeční selhání, diastolické | Psoriasis vulgaris | Kardiovaskulární rizikový faktor | Srdeční selhání, systolické | Dysfunkce levé komory | Psoriasis Universalis | Psoriáza na obličeji | Psoriasis diffusa a další podmínkyDánsko
-
Centre of Evidence of the French Society of DermatologyNáborPsoriáza | Psoriasis vulgaris | Psoriáza pokožky hlavy | Psoriatický plak | Psoriasis Universalis | Psoriasis Palmaris | Psoriatická erytrodermie | Psoriatický hřebík | Psoriáza Guttate | Inverzní psoriáza | Pustulární psoriázaFrancie
-
Clin4allNáborPsoriáza pokožky hlavy | Psoriáza hřebík | Psoriasis Palmaris | Genitální psoriáza | Psoriasis PlantarisFrancie
-
Chulalongkorn UniversityKing Chulalongkorn Memorial HospitalZatím nenabíráme
-
Radboud University Medical CenterUniversity Hospital, Ghent; ZonMw: The Netherlands Organisation for Health... a další spolupracovníciAktivní, ne náborPsoriáza | Psoriasis vulgarisHolandsko, Belgie
-
University Hospital, Gentofte, CopenhagenDokončenoPsoriasis vulgaris
-
South Valley UniversityDokončeno
-
AkesoDokončeno
-
University Hospital, GhentKU Leuven; University GhentUkončeno
Klinické studie na etanercept
-
EMSStaženoRevmatoidní artritidaBrazílie
-
Shanghai Celgen Bio-Pharmaceutical Co.,LtdNeznámýPsoriáza | Plaková psoriázaČína
-
mAbxience Research S.L.Nábor
-
AmgenDokončenoArtritida, revmatoidní; Artritida, psoriatikaSpojené státy, Portoriko
-
AmgenDokončeno
-
PfizerDokončenoPsoriázaŠpanělsko, Francie, Německo, Krocan, Spojené království, Maďarsko, Řecko, Itálie, Spojené arabské emiráty
-
PfizerDokončenoSpondylitida, ankylozující
-
AmgenWyeth is now a wholly owned subsidiary of PfizerDokončenoZánět | Psoriáza
-
Wyeth is now a wholly owned subsidiary of PfizerDokončenoRevmatoidní artritidaJaponsko